Firstly, to screen blood exosomal multi-omics (transcriptomics, proteomics, metabolomics) and lung radiomics (HRCT, Xe129MRI) biomarkers that can predict efficacy and prognosis in severe eosinophilic ACOS (asthma-COPD overlap) patients treated with different biologics (benralizumab, mepolizumab, dupilumab). Then, to prospectively follow patients for 48 weeks after biologic initiation and collect clinical data, blood samples, and imaging features. Finally, to build a multi-dimensional predictive model for efficacy and prognosis of severe eosinophilic ACOS.
Age ≥ 14 years
Clinician decision to start biologic (benralizumab, mepolizumab, or dupilumab) for severe eosinophilic ACOS
Blood eosinophils ≥150/μL within 3 months prior to informed consent, or ≥300/μL within 1 year prior
Signed written informed consent
Currently participating in any other interventional clinical trial
Known allergy or hypersensitivity to any component of the study drugs
Any type of malignancy
Prior or current biologic treatment for ACOS